Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications

*co-first author; #co-corresponding author

Miao, B*; Hu, Z*; Mezzadra, R*; Hoeijmakers, L*; Fauster, A; Du, S; Yang, Z; Sator-Schmitt, M; Engel, H; Li, X; Broderick, C; Jin, G; Gomez-Eerland, R; Rozeman, L; Lei, X; Matsuo, H; Yang, C; Hofland, I; Peters, D; Broeks, A; Laport, E; Fitz, A; Zhao, X; Mahmoud, M. A. A; Ma, X; Sander, S; Liu, H. K; Cui, G; Gan, Y; Wu, W; Xiao, Y; Heck, A. J. R; Guan, W; Lowe, S. W; Horlings, H. M; Wang, C; Brummelkamp, T. R; Blank, C. U#; Schumacher, T. N. M.# & Sun, C#. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 41, 1-12, doi:10.1016/j.ccell.2023.08.008 (2023).

Lei, X., Khatri, I., de Wit, T., de Rink, I., Nieuwland, M., Kerkhoven, R., van Eenennaam, H., Sun, C., Garg, A. D., Borst, J. & Xiao, Y. CD4(+) helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat Commun 14, 217, doi:10.1038/s41467-022-35615-5 (2023)

Li, Y.*, Yang, C.*, Liu, Z.*, Du, S.*, Can, S., Zhang, H., Zhang, L., Huang, X., Xiao, Z., Li, X., Fang, J., Qin, W., Sun, C.#, Wang, C.#, Chen, J.# & Chen, H.# Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. Molecular Cancer 21, 2, doi:10.1186/s12943-021-01462-z (2022).

Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., Jochems, F., Yang, Y., Bosma, A., Hijmans, E. M., de Groot, M. H. P., Vegna, S., Cui, D., Zhou, Y., Ling, J., Wang, H., Guo, Y., Zheng, X., Isima, N., Wu, H., Sun, C., Beijersbergen, R. L., Akkari, L., Zhou, W., Zhai, B., Qin, W. & Bernards, R. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730-734, doi:10.1038/s41586-021-03741-7 (2021).

Sun, C.*, Mezzadra, R.* & Schumacher, T. N.* Regulation and Function of the PD-L1 Checkpoint. Immunity 48, 434-452, doi:10.1016/j.immuni.2018.03.014 (2018).

Mezzadra, R.*, Sun, C.*, Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., Broeks, A., Horlings, H. M., Wessels, L. F. A., Blank, C. U., Xiao, Y., Heck, A. J. R., Borst, J., Brummelkamp, T. R. & Schumacher, T. N. M. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106-110, doi:10.1038/nature23669 (2017)

Sun, C.*, Wang, L.*, Huang, S.*, Heynen, G. J., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. & Bernards, R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122, doi:10.1038/nature13121 (2014)

Papadakis, A. I.*, Sun, C.*, Knijnenburg, T. A., Xue, Y., Grernrum, W., Holzel, M., Nijkamp, W., Wessels, L. F., Beijersbergen, R. L., Bernards, R. & Huang, S. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res 25, 445-458, doi:10.1038/cr.2015.16 (2015).

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., Schlicker, A., Wessels, L. F., Smit, E. F., Thunnissen, E., Halonen, P., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., Bardelli, A., Trusolino, L. & Bernards, R. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 7, 86-93, doi:10.1016/j.celrep.2014.02.045 (2014).

Lamba, S.*, Russo, M.*, Sun, C.*, Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F. & Bardelli, A. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep 8, 1475-1483, doi:10.1016/j.celrep.2014.07.033 (2014).

Sun, C. & Bernards, R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 39, 465-474, doi:10.1016/j.tibs.2014.08.010 (2014).

Prahallad, A.*, Sun, C.*, Huang, S.*, Di Nicolantonio, F.*, Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A. & Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103, doi:10.1038/nature10868 (2012)

Huang, S., Holzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F. H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., Ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R. L., Wessels, L. F. & Bernards, R. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151, 937-950, doi:10.1016/j.cell.2012.10.035 (2012).

Carette, J. E., Guimaraes, C. P., Wuethrich, I., Blomen, V. A., Varadarajan, M., Sun, C., Bell, G., Yuan, B., Muellner, M. K., Nijman, S. M., Ploegh, H. L. & Brummelkamp, T. R. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 29, 542-546, doi:10.1038/nbt.1857 (2011).

to top
powered by webEdition CMS